Provided by Tiger Trade Technology Pte. Ltd.

Myriad Genetics

3.18
-0.0400-1.24%
Post-market: 3.210.0300+0.94%19:59 EDT
Volume:3.03M
Turnover:9.31M
Market Cap:304.01M
PE:-2.64
High:3.22
Open:2.95
Low:2.92
Close:3.22
52wk High:8.59
52wk Low:2.74
Shares:95.60M
Float Shares:79.40M
Volume Ratio:2.08
T/O Rate:3.82%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2031
EPS(LYR):-3.9514
ROE:-32.54%
ROA:-8.59%
PB:1.00
PE(LYR):-0.80

Loading ...

Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business

GlobeNewswire
·
May 06

Myriad Genetics Inc expected to post a loss of 7 cents a share - Earnings Preview

Reuters
·
May 02

Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan

GlobeNewswire
·
Apr 30

Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026

GlobeNewswire
·
Apr 29

Myriad reports new MONITOR-Breast trial results for Precise MRD at AACR 2026

Reuters
·
Apr 16

Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026

GlobeNewswire
·
Apr 16

Myriad Genetics announces annual shareholder meeting webcast

Reuters
·
Apr 15

Japan health ministry approves Myriad MyChoice test as Lynparza companion for prostate cancer

Reuters
·
Apr 14

Myriad says Precise MRD ovarian cancer test predicts recurrence risk after adjuvant therapy

Reuters
·
Apr 09

Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting

GlobeNewswire
·
Apr 09

FDA approves Myriad MyChoice CDx as Zejula companion diagnostic for advanced ovarian cancer

Reuters
·
Mar 18

Myriad Genetics Receives FDA Approval of the Mychoice Cdx Test as the Companion Diagnostic for Zejula (Niraparib) for Patients With Ovarian Cancer

THOMSON REUTERS
·
Mar 18

Veracyte Appoints Kevin Haas as Chief Development and Technology Officer

MT Newswires Live
·
Mar 17

Veracyte appoints Kevin Haas as chief development and technology officer

Reuters
·
Mar 17